Maria Salgado consults on complex business litigation involving pharmaceuticals and healthcare, with a focus on antitrust and competition, the False Claims Act, intellectual property and marketing issues. She has particular expertise with alleged violations of the federal Anti-Kickback Statute and overpayment issues in connection with Medicare. Her economic analyses also cover high tech, airlines, online advertising and credit card markets.
Dr Salgado has extensive antitrust and competition experience. She has evaluated a range of competitive effects, including those related to exclusive supply arrangements, life-cycle management strategies and delayed generic entry of pharmaceutical drugs. She has worked on product and geographic market definition issues, particularly for prescription drugs, physician services and health insurance.
In intellectual property matters, Dr Salgado has evaluated whether branded manufacturers would suffer irreparable harm due to the “at-risk” launch of generic drugs in the context of Hatch-Waxman Paragraph IV cases. She has analysed commercial success issues related to obviousness claims and conducted valuation of early-stage drugs. Her patent expertise includes high-tech industries, where she has calculated patent infringement damages and assessed the role of standard setting organisations and RAND commitments.
Dr Salgado has significant marketing and promotion case experience. She has analysed class certification issues related to the off-label promotion of pharmaceutical drugs, estimated the impact of “all natural” claims on sales and prices, and consulted on survey design and implementation.
Dr Salgado’s research has appeared in Health Affairs, The Antitrust Source, Nature Reviews, and the Antitrust Health Care Chronicle. She holds a PhD from Northwestern University.